The European Medicines Agency (EMA) has recommended the approval of Lecanemab, an antibody that may slow the progression of Alzheimer’s disease, specifically for patients with light cognitive impairment and minimal risk factors. This marks the first EU endorsement targeting the disease’s underlying processes, rather than just alleviating symptoms. The recommendation is limited to patients with one or no copies of the ApoE4 gene variant, minimizing severe side effects. With approximately one million affected individuals in Germany, Lecanemab could become accessible soon, though a coordinated rollout in medical centers will take time.